20
Participants
Start Date
May 30, 2024
Primary Completion Date
April 20, 2025
Study Completion Date
May 30, 2025
Lenvatinib
Lenvatinib(oral,12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day); Adebrelimab(intravenous drip,1200mg once every 3 weeks); GEMOX(intravenous drip,Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip,Oxaliplatin, 100mg/m2, was given every 3 weeks)
Tongji Hospital, Wuhan
Zhiyong Huang
OTHER